Conjugated linoleic acid prompts bone formation in ovariectomized osteoporotic rats and weakens osteoclast formation after treatment with ultraviolet B

Shan, Zhongshu; Zhao, Yanyan; Qiu, Zhixue; Suonan, Angxiu; Gu, Yun; Luo, Jun; Bi, Haibo; Luo, Wei; Xiong, Rui; Ma, Sisi; Zhao, He; Chen, Liang

doi:10.21037/atm-21-934

Cited by 4 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was interesting to note that ICA administration also significantly up-regulated the precursor of stearidonic acid, i.e., linoleic acid, by FC of 1.36 ( p < 0.05), which was 1.32 times of E2 group ( p < 0.05). The relationships between linoleic acid and bone biology have been widely studied and recently verified to promote bone formation in OVX rats by co-working with ultraviolet B treatment ( 55 , 56 ). L-Saccharopine is an important metabolite in amino acid metabolism and often decrease during the progression of OP and PMOP ( 57 , 58 ).…”

Section: Discussionmentioning

confidence: 99%

Effects of Icariin on Modulating Gut Microbiota and Regulating Metabolite Alterations to Prevent Bone Loss in Ovariectomized Rat Model

Wang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Postmenopausal osteoporosis (PMOP) is an estrogen deficiency-induced bone loss, which has been shown an association with an altered gut microbiota (GM). Gut microbiota-bone axis has been recognized as a crucial mediator for bone homeostasis. Icariin (ICA) is an effective agent to delay bone loss by regulating the bone homeostasis. Thus, we hypothesize that ICA can prevent bone loss by modulating GM and regulating metabolite alterations. The effects of ICA on bone metabolism improvement in ovariectomized (OVX) rats and their relationships with the GM and fecal metabolites were investigated. Micro-computed tomography (micro-CT) and hematoxylin-eosin (HE) staining showed a typical bone boss in OVX group, while ICA or estradiol (E2) administration exhibited positive effects on bone micro-architecture improvement. The GM such as Actinobacteria, Gammaproteobacteria, Erysipelotrichi, Erysipelotrichales, Enterobacteriales, Actinomycetales, Ruminococcus and Oscillospira significantly correlated to serum bone Gla-protein (BGP), receptor activator of nuclear factor-κB (RANK), receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG) and tartrate resistant acid phosphatase (TRACP). Further t-test revealed a substantial variation of the GM and fecal metabolites in different treatments. Among them, Lachnoclostridium, Butyricimonas, Rikenella, Paraprevolla, Adlercreutzia, Enterorhabdus, Anaerovorax, Allobaculum, Elusimicrobium, Lactococcus, Globicatella and Lactobacillus were probably the key microbial communities driving the change of bile acid, amino acid and fatty acid, thereby leading to an improvement of PMOP. The significant up-regulation of L-Saccharopine, 1-Aminocyclohexadieneacid and linoleic acid after ICA administration suggested important contributions of amino acid and fatty acid metabolisms in the prevention and treatment of PMOP. Taken together, our study has provided new perspectives to better understand the effects of ICA on PMOP improvement by regulating GM and the associated fecal metabolites. Our findings contribute to develop ICA as a potential therapy for PMOP.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Icariin on Modulating Gut Microbiota and Regulating Metabolite Alterations to Prevent Bone Loss in Ovariectomized Rat Model

Wang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…We found that BSZJD has potential anti-osteoporotic effects through mass spectrometry analysis-network pharmacology-molecular docking. The active ingredients of BSZJD possess similar pharmacological effects, including immunomodulatory, anti-in ammatory and antioxidant effects [10,11] . Triterpenoids (e.g., porinic acid) can regulate the RANKL-medi.ated NF-κb and Nfatc1 signaling pathway, inhibit RANKL and RANKJ binding, and thus inhibit osteoclast proliferation and differentiation [12] .…”

Section: Discussionmentioning

confidence: 99%

The potential mechanism of Bu Shen Zhuang Jin Decoction in the treatment of anti-osteoporosis based on mass spectrometry analysis-network pharmacology-molecular docking

Zhou,

Zhong,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background To investigate the potential mechanism of Bu Shen Zhuang Jin Decoction(BSZJD) in the treatment of anti-osteoporosis based on mass spectrometry analysis-network pharmacology-molecular docking.Methods We used Waters Synapt G2-Si Qtof high-resolution mass spectrometry and Unifi software to analyze the chemical constituents of BSZJD. Querying the targets of ingredients through the Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicines (BATMAN-TCM). GeneCards, OMIM databases were searched for osteoporosis targets. Venny online analysis tool was used to obtain ingredients-disease common targets, construct drug-ingredient-target-disease network by Cytoscape software, and screen core ingredients based on node degree value. Based on disease-ingredient common targets, STRING database and Cytoscape software constructed protein-protein interaction networks and assigned core targets based on node degree value. Metascape was analyzed for GO and KEGG enrichment. The main ingredients and core targets were molecularly docked and the results were visualized by Pymol.Results There are 107 active ingredients in BSZJD. AKT1, ALB, INS, IL6, and TNF were from the 157 targets identified by the protein-protein interaction network. The PI3K-AKT and osteoclast differentiation signaling pathways were identified as possible anti-osteoporosis pathways by the enrichment analysis. Molecular docking confirms that the core ingredients and the core targets have strong binding capability.Conclusion Through mass spectrometry analysis-network pharmacology-molecular docking, we speculate that the BSZJD may play an anti-osteoporotic role by modulating the PI3K/AKT and osteoclast differentiation signaling pathways, which may provide a new idea for the treatment of osteoporosis.

show abstract

“…The production of mineralized nodules of osteoblasts was observed (Rahman et al., 2014). Continuous administration of different concentrations of CLA (1.4/2.8/4.2 mmol/kg) for 24 weeks stimulated new bone formation and inhibited TRAP activity in a dose‐dependent manner (Shan et al., 2021). In a Mendelian randomization study of 53,236 patients with osteoporosis, it was established that consumption of dairy products rich in omega‐3 fatty acids reduced serum PTH and RANKL (Wang, Zhang, et al., 2022).…”

Section: Role Of Milk Components On Osteoporosis Modulationmentioning

confidence: 99%

New insights into dairy management and the prevention and treatment of osteoporosis: The shift from single nutrient to dairy matrix effects—A review

Wang,

Zhao,

Yang

et al. 2024

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Dairy is recognized as a good source of calcium, which is important for preventing osteoporosis. However, the relationship between milk and bone health is more complex than just calcium supplementation. It is unwise to focus solely on observing the effects of a single nutrient. Lactose, proteins, and vitamins in milk, as well as fatty acids, oligosaccharides, and exosomes, all work together with calcium to enhance its bioavailability and utilization efficiency through various mechanisms. We evaluate the roles of dairy nutrients and active ingredients in maintaining bone homeostasis from the perspective of the dairy matrix effects. Special attention is given to threshold effects, synergistic effects, and associations with the gut–bone axis. We also summarize the associations between probiotic/prebiotic milk, low‐fat/high‐fat milk, lactose‐free milk, and fortified milk with a reduced risk of osteoporosis and discuss the potential benefits and controversies of these dairy products. Moreover, we examine the role of dairy products in increasing peak bone mass during adolescence and reducing bone loss in old age. It provides a theoretical reference for the use of dairy products in the accurate prevention and management of osteoporosis and related chronic diseases and offers personalized dietary recommendations for bone health in different populations.

show abstract

Conjugated linoleic acid prompts bone formation in ovariectomized osteoporotic rats and weakens osteoclast formation after treatment with ultraviolet B

Cited by 4 publications

References 42 publications

Effects of Icariin on Modulating Gut Microbiota and Regulating Metabolite Alterations to Prevent Bone Loss in Ovariectomized Rat Model

Effects of Icariin on Modulating Gut Microbiota and Regulating Metabolite Alterations to Prevent Bone Loss in Ovariectomized Rat Model

The potential mechanism of Bu Shen Zhuang Jin Decoction in the treatment of anti-osteoporosis based on mass spectrometry analysis-network pharmacology-molecular docking

New insights into dairy management and the prevention and treatment of osteoporosis: The shift from single nutrient to dairy matrix effects—A review

Contact Info

Product

Resources

About